Home > Insider Trading > Filing (0001209191-20-025677)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1070494	Acadia Pharmaceuticals Inc	ACAD	Pharmaceutical Preparations (2834)	061376651

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1432545	R. Srdjan Stankovic	C/O Acadia Pharmaceuticals Inc. 3611 Valley Centre Drive, Ste. 300 San Diego CA 92130	President	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-04-23	7,074	$19.65	13,101	No	4	M	Direct
Common Stock	Acquisiton	2020-04-23	11,875	$21.28	24,976	No	4	M	Direct
Common Stock	Disposition	2020-04-23	18,949	$50.07	6,027	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2020-04-23	7,074	$0.00	7,074	$19.65
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2020-04-23	11,875	$0.00	11,875	$21.28

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
8,551		2026-03-14	No	4	M	Direct
35,625		2028-10-15	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 8, 2019.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The stock option is fully vested and exercisable.
25% of the shares subject to the Stock Option vested and became exercisable on October 15, 2019. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.